Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).

Joshua Sabari, MD, a thoracic medical oncologist, Perlmutter Cancer Center, NYU Langone Health, discusses actionable mutations in advanced non–small cell lung cancer (NSCLC). KRAS mutations as a whole ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory ...

Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

KRAS-mutant circulating tumor (ct)DNA is associated with worse overall survival (OS) in localized pancreatic ductal ...

Mutations in KRAS drive PDAC. (A) Illustration depicting different stages of PDAC, in which tumors originating in the pancreas (stage 1) first extend to lymph nodes and bile ducts (stage 2), then ...

KRAS G12C occurs in ~3%–4% of CRC, translating to a sizable metastatic population with limited options and strong rationale for KRAS G12C inhibition strategies. Dual KRAS–EGFR blockade leverages ...

Researchers have long sought new ways to disable or inhibit cancer-driving proteins. Many transformative therapies have been built on this paradigm. Yet, for many of these proteins, such as KRAS, ...

The pancreas is in the upper part of the abdomen. (Sebastian Kaulitzki/Science Photo Library/Getty Images) Pancreatic ductal ...